Evidence Strategy (HEOR)

In today’s competitive markets, the challenge is to articulate and quantify the value of a product— and also to differentiate it from competitors and the existing standard of care, to support a strategic price point and to ensure a successful medical communication, market access and reimbursement strategy.  

Trinity’s Evidence Strategy team helps clients to develop a compelling value story, demonstrate must-have evidence and drive scientific dissemination to communicate your product’s value story: 

The Evidence Strategy team offers a complete suite of Health Economics and Outcomes Research (HEOR) services to help differentiate the value of a product vs. the competition.  

Leveraging best-in-class, scientifically driven, publication-quality primary and secondary research methods, we help our clients demonstrate the holistic value of their assets across the product lifecycle — from early clinical development all the way to launch and post-launch. 

• Evidence-Based Value Arguments

  For HEOR leaders focusing on evidence planning, evidence generation and scientific dissemination, RWE provides a solid foundation that allows them to address their key research questions around the patient, burden of illness and therapy/treatment landscape. The core challenge is two-fold:

  • Pre-launch — demonstrate and measure unmet needs in the current marketplace to pave the way for the upcoming launch
  • Post-launch — articulate the measurable value of an asset and differentiate it to ensure a successful market access and reimbursement strategy
• Answering Important Business Questions

  Trinity’s integrated RWE and Evidence Strategy teams have collaboratively helped hundreds of clients address their most important business questions:

  • What are the unmet needs in the current treatment paradigm for Disease X?
  • What is the epidemiology of Disease X? Are there sub-types of interest?
  • How do I identify the right patients in the absence of ICD-9 / 10 codes?
  • What is the patient journey for someone suffering from Disease Y?
  • What are the treatment patterns, therapy use, switch / adherence behaviors?
  • What is the comparative effectiveness of therapies in this market / class?
  • What SE and AE are associated with these treatments?
  • What is the overall Healthcare Resource Utilization (HCRU)?
  • What is the holistic cost of care?
  • Strategically, what are the pain points, unmet needs and gaps where Treatment Z can add value?

  Find out more about Trinity EvidenceFirst – Helping clients navigate through the complexities of RWE analysis.

Our Team

Trinity’s Evidence Strategy team features advanced degrees including multiple PhD-level experts – we consistently deliver high-quality insights and products to meet internal and external stakeholder needs. 

Meet Our Evidence Strategy Experts

The team is led by an Nandini Hadker, an Economist who presents annually at ISPOR, ISPOR-EU, AMCP, AMCP-Nexus and strategic clinical conferences who has authored numerous white papers, academic research posters and peer-reviewed manuscripts in reputed journals.  

Nandini Hadker is supported by two Managing Directors, Matt O’Hara and Jeff Skaar, who are also leaders in the evidence generation and HEOR space and bring deep expertise in the sphere of HEOR, evidence generation and scientific dissemination.